
Opinion|Videos|February 12, 2025
BOND-003 Trial and Cretostimogene for Treatment of NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune stimulation via granulocyte-macrophage colony-stimulating factor expression.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is cretostimogene grenadenorepvec? Please describe its mechanism of action.
- Discuss the phase 3 BOND-003 clinical trial investigating the use of the intravesical immunotherapy cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive disease that was recently presented at the Society of Urologic Oncology 2024.
- What are your impressions of the BOND-003 data?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
2
Registry launches to assess real-world clinical utility of ArteraAI Prostate Test
3
Focal therapy for prostate cancer frequently used outside guideline-supported groups
4
Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC
5









